2017
Greater Efficacy with Secukinumab Treatment is Associated with Greater Psoriasis Symptom Relief: Results from Secukinumab Clinical Trial Data
Gottlieb A, Strober B, Lebwohl M, Kaufmann R, Pariser D, Narbutas R, Nyirady J, Zhao Y, Herrera V, McLeod L, Odom D, Elewski B. Greater Efficacy with Secukinumab Treatment is Associated with Greater Psoriasis Symptom Relief: Results from Secukinumab Clinical Trial Data. Journal Of Psoriasis And Psoriatic Arthritis 2017, 2: 73-80. DOI: 10.1177/247553031700200206.Peer-Reviewed Original ResearchPsoriasis-related itchingWeek 12Disease severityBenefits of secukinumabInterleukin-17A antagonistSevere plaque psoriasisPatient-reported symptomsClinical trial dataDisease severity scoreQuality of lifeTraditional clinical measuresBackground PsoriasisPASI responseSecukinumab treatmentPlaque psoriasisComplete reliefSymptom reliefSeverity scoreClinical dataResponder statusClinical measuresGreater efficacyTrial dataSecukinumabTreatment effects
2016
Secukinumab Provides Clearer Skin and Better Control on Patient-Reported Psoriasis Symptoms of Itching, Pain, and Scaling than Placebo and Etanercept
Strober B, Sigurgeirsson B, Popp G, Sinclair R, Krell J, Stonkus S, Septe M, Elewski B, Gottlieb A, Zhao Y, Herrera V, Mordin M, Odom D, Papavassilis C, Nyirady J, Lebwohl M. Secukinumab Provides Clearer Skin and Better Control on Patient-Reported Psoriasis Symptoms of Itching, Pain, and Scaling than Placebo and Etanercept. Journal Of Psoriasis And Psoriatic Arthritis 2016, 1: 167-174. DOI: 10.1177/247553031600100406.Peer-Reviewed Original ResearchPsoriasis-related itchingSevere plaque psoriasisPhase 3 studyComplete symptom reliefWeeks of treatmentProportion of respondersGreater symptom improvementSymptom respondersPlaque psoriasisPsoriasis symptomsSymptom reliefComplete reliefSustained efficacySymptom improvementPsoriasis treatmentResults SubjectsSecukinumabEtanerceptItchingPainClear skinPlaceboMonoclonal antibodiesTreatment effectsPatientsSecukinumab improves patient‐reported psoriasis symptoms of itching, pain, and scaling: results of two phase 3, randomized, placebo‐controlled clinical trials
Strober B, Sigurgeirsson B, Popp G, Sinclair R, Krell J, Stonkus S, Septe M, Elewski BE, Gottlieb AB, Zhao Y, Tran MH, Karpov A, McLeod LD, Mordin M, Papavassilis C, Nyirady J, Lebwohl M. Secukinumab improves patient‐reported psoriasis symptoms of itching, pain, and scaling: results of two phase 3, randomized, placebo‐controlled clinical trials. International Journal Of Dermatology 2016, 55: 401-407. PMID: 26866518, DOI: 10.1111/ijd.13236.Peer-Reviewed Original ResearchConceptsWeek 12Multicenter phase 3 studyPlacebo-controlled clinical trialInterleukin-17A antagonistPsoriasis-related itchingPlacebo treatment groupsSevere plaque psoriasisPhase 3 studyWeeks of treatmentProportion of subjectsPlaque psoriasisSevere psoriasisPsoriasis symptomsSystemic therapySymptom diaryClinical trialsSecukinumabTreatment responsePlaceboItchingPainTreatment groupsPhase 3PsoriasisAdults